Delgocitinib Cream for Chronic Hand Dermatitis: Efficacy, Safety and Clinical Application

Yash Jani, BS¹ and Austinn Miller, MD^2,3,4

¹Medical College of Georgia, Augusta University, Augusta, GA, USA
²Dermatology Associates of Tallahassee, Tallahassee, FL, USA
³University of Central Florida, Tallahassee, FL, USA
⁴Florida State University, Tallahassee, FL, USA

Conflicts of interest: The authors have no relevant conflicts of interest to disclose. Funding sources: None.

ABSTRACT
Chronic hand dermatitis (CHD), also referred to as chronic hand eczema, is a persistent inflammatory skin disorder characterized by erythema, fissuring, scaling, lichenification, and significant pruritus and pain. The condition is often debilitating, particularly because the hands are constantly exposed to mechanical friction, detergents, irritants, and environmental stressors. Traditional treatments such as topical corticosteroids, calcineurin inhibitors, phototherapy, and systemic immunomodulators are limited by safety concerns, incomplete efficacy, or poor long-term tolerability. Delgocitinib 2% cream, a non-steroidal, topical pan–Janus kinase (JAK) inhibitor, represents the first targeted therapy specifically approved for moderate-to-severe CHD in adults. Through inhibition of JAK1, JAK2, JAK3, and tyrosine kinase 2, delgocitinib broadly suppresses multiple cytokine pathways involved in hand eczema pathogenesis. Clinical trials have demonstrated significant improvement in Investigator’s Global Assessment scores, Hand Eczema Severity Index, pruritus, pain, and quality of life, along with sustained benefit in long-term extension studies. Safety data reveal minimal systemic absorption, no steroid-associated skin atrophy, and a favorable tolerability profile without box warnings. This review examines the pathophysiology of CHD and the clinical evidence supporting delgocitinib as an effective, steroid-sparing therapeutic option.

Keywords: chronic hand dermatitis, chronic hand eczema, delgocitinib, JAK inhibitor, topical therapy, pan-JAK inhibition, hand eczema treatment, inflammatory skin disease, topical immunomodulator, eczema management

Introduction

Chronic hand dermatitis (CHD) is a multifactorial inflammatory skin disease affecting millions of individuals worldwide and is one of the most common dermatologic conditions observed in clinical practice. It is marked by recurrent flares of erythema, scaling, vesiculation, hyperkeratosis, fissuring, and lichenification.¹ Patients frequently report severe pruritus, burning, and pain that interfere with daily activities, occupational tasks, and sleep.² Because the hands are constantly exposed to irritants, chemicals, temperature changes, and repetitive frictional trauma, lesions often heal slowly and recur rapidly, perpetuating a cycle of inflammation and barrier disruption.

The prevalence of CHD is estimated at 5-10% in the general population but is significantly higher in occupations involving “wet work,” including healthcare workers, hairdressers, food service employees, laboratory personnel, and cleaning staff.³ The condition is associated with considerable economic and psychosocial burden, with many patients requiring workplace modifications, medical leave, or job changes. Quality of life studies consistently demonstrate embarrassment, social withdrawal, functional impairment, and emotional distress, highlighting the importance of effective long-term disease control.^2,4

Pathophysiologically, CHD encompasses several overlapping etiologies. Irritant contact dermatitis results from repeated exposure to water, soaps, solvents, and chemicals that erode the skin barrier.⁵ Allergic contact dermatitis arises from sensitization to allergens such as rubber accelerators, preservatives, fragrances, and metals. Atopic hand eczema is characterized by baseline barrier dysfunction and type 2 inflammation.⁵ Hyperkeratotic hand eczema and recurrent vesicular (dyshidrotic) eczema represent additional phenotypes.⁶ Many patients exhibit mixed features, and subtype identification can be challenging in long-standing disease. Regardless of etiology, immune dysregulation involving T helper 1 (Th1), Th2, Th17, and Th22 cytokine pathways contributes significantly to chronic inflammation.⁶

For decades, treatment options have remained limited. Emollients and barrier creams are essential but insufficient for moderate-to-severe disease. High-potency topical corticosteroids are widely used due to their rapid anti-inflammatory effects but cannot be used chronically due to risks of atrophy, telangiectasia, impaired healing, and tachyphylaxis.⁷ Calcineurin inhibitors offer a steroid-sparing option but are associated with stinging, limited penetration in hyperkeratotic skin, and modest efficacy in many patients.⁸ Phototherapy may help but requires frequent clinic attendance. Systemic treatments, including alitretinoin, cyclosporine, methotrexate, and biologics such as dupilumab, are reserved for severe cases but present cost-related, safety-related, and monitoring-related limitations.⁹

This substantial unmet therapeutic need has driven interest in targeted, steroid-sparing topical agents capable of suppressing multiple inflammatory pathways with an acceptable long-term safety profile. Delgocitinib, the first topical pan-Janus kinase (JAK) inhibitor approved for CHD, fulfills this need by inhibiting multiple downstream cytokine signals and providing broad anti-inflammatory effects in a localized, minimally absorbed form.^10,11

Mechanism of Action

Delgocitinib is a potent, small-molecule inhibitor of all four JAK family members: JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2).¹² These kinases mediate signal transduction for numerous cytokine receptors involved in innate and adaptive immunity. Cytokine binding activates JAKs, which phosphorylate signal transducers and activators of transcription (STAT) factors that modulate inflammatory gene expression. In CHD, multiple cytokines implicated in barrier dysfunction, immune activation, and pruritus, including interleukin (IL)-4, IL-13, IL-31, IL-22, IL-17, IL-2, and interferon-γ, signal through JAK–STAT pathways.¹¹

By inhibiting JAK activation, delgocitinib decreases STAT phosphorylation and ultimately reduces transcription of downstream inflammatory mediators. This leads to diminished infiltration of activated T cells and dendritic cells, decreased production of cytokines and chemokines that propagate inflammation, and normalization of keratinocyte proliferation and differentiation.^10,11 Importantly, delgocitinib increases intracellular cyclic adenosine monophosphate (cAMP) and interrupts inflammatory feedback loops that drive chronic disease. The result is improved skin barrier integrity, reduced erythema and scaling, decreased fissuring, and rapid relief of itch and pain.^10,11

Topical application allows for high drug concentration in the epidermis and superficial dermis, where JAK–STAT signaling is most active, while systemic absorption remains minimal. This pharmacologic profile results in broad immunomodulation of cutaneous inflammation without the systemic adverse effects associated with oral JAK inhibitors.

Clinical Trials

Clinical development of delgocitinib cream included phase 2 dose-finding studies, two pivotal phase 3 randomized controlled trials, and a year-long extension study, all of which demonstrated meaningful clinical improvement and an excellent safety profile.

Phase 2 Dose-Finding Studies

Early phase 2 studies evaluated multiple concentrations of delgocitinib cream in adults with moderate-to-severe CHD.¹³ These dose-ranging, vehicle-controlled trials assessed once- or twice-daily application across a spectrum of strengths, including the 2% (20 mg/g) formulation that would ultimately advance to registration studies. Delgocitinib consistently produced significant reductions in erythema, scaling, fissuring, and hyperkeratosis compared with vehicle, and patients reported meaningful improvements in pruritus, burning, and pain.¹¹ Higher concentrations demonstrated greater and more durable responses, with the 20 mg/g strength achieving the most robust improvements and maintaining favorable tolerability.¹⁴ These findings provided the rationale for selecting the 2% cream for phase 3 development.

Pivotal Phase 3 Trials: DELTA 1 and DELTA 2

The efficacy and safety of delgocitinib 2% cream were subsequently confirmed in two large, multicenter, randomized, double-blind, vehicle-controlled phase 3 trials (DELTA 1 and DELTA 2).¹⁴ Together enrolling nearly 1,000 adults, these studies included participants with moderate-to-severe CHD involving palmar and dorsal hand surfaces and defined by strict, validated clinical severity criteria. Subjects applied delgocitinib or vehicle twice daily for 16 weeks.

The primary endpoint for both trials was Investigator’s Global Assessment for Chronic Hand Eczema (IGA-CHE) treatment success, achieving a score of “clear” or “almost clear” with at least a two-grade improvement from baseline.¹⁴ Secondary endpoints included the proportion of patients achieving substantial or near-complete improvement on the Hand Eczema Severity Index (HECSI-75 and HECSI-90), as well as changes in patient-reported itch, pain, and quality of life scores.

Delgocitinib achieved statistically significant and clinically meaningful improvements across all major outcomes.¹⁴ IGA-CHE success rates at week 16 were approximately three times higher in the delgocitinib groups compared with vehicle.¹⁴ More than half of treated patients achieved HECSI-75, and roughly one-third achieved HECSI-90, reflecting substantial clinical clearance. Notably, improvements in pruritus and pain emerged early, often within the first few weeks of therapy, and continued to rise through week 16.¹⁴ These symptomatic gains translated into marked improvements in quality of life measures, with patients reporting decreased discomfort, improved hand function, and greater ability to perform occupational and daily tasks.

Long-Term Extension Study

Patients who completed DELTA 1 or DELTA 2 were eligible to continue treatment in a 36-week open-label extension, providing up to 52 weeks of total exposure.¹⁵ Long-term therapy reinforced the durability of delgocitinib’s benefit. Patients who had responded during the randomized phase generally maintained or further improved their disease control throughout the extension, while those initially assigned to vehicle experienced rapid improvement once switched to active treatment.¹⁵ Importantly, no new safety concerns emerged over this prolonged use, and the overall adverse event profile remained consistent with earlier trials. These findings are particularly relevant for a disease characterized by chronic relapses, underscoring delgocitinib’s suitability for ongoing management. Importantly, analyses from the DELTA 3 extension also evaluated outcomes following treatment withdrawal and demonstrated that a subset of patients maintained meaningful disease control after discontinuation, with the most durable responses observed among high responders, suggesting that delgocitinib may confer sustained disease modulation beyond continuous therapy.¹⁵

Summary

Across phase 2, phase 3, and long-term extension studies, delgocitinib cream demonstrated consistent, dose-dependent, and clinically meaningful improvements in CHD. The trials collectively confirmed its ability to reduce disease severity, alleviate symptoms, enhance quality of life, and maintain stable long-term control, all with an excellent safety profile. These outcomes establish delgocitinib as a valuable therapeutic option for patients requiring effective, steroid-sparing treatment of CHD.

Safety and Tolerability

Across all clinical phases, delgocitinib cream was well tolerated, with a safety profile comparable to vehicle.^13,14 No treatment-related serious adverse events were observed. Most adverse events were mild and consisted of transient application-site reactions such as burning, stinging, or pruritus, which diminished as inflammation improved. Low-grade nasopharyngitis and headache, common in the general population, occurred at similar frequencies in both treatment and vehicle groups.^13,14

Importantly, no cases of skin atrophy, telangiectasias, or delayed wound healing were reported, in contrast to chronic topical corticosteroid use, which poses long-term safety concerns on the hands.¹⁶ Laboratory monitoring during phase 3 trials revealed no significant changes in complete blood counts, hepatic enzymes, lipids, or creatine phosphokinase.^13,14 No increased rates of opportunistic infections, malignancies, or thromboembolic events were observed, reinforcing the minimal systemic absorption and localized activity of the topical formulation.

Long-term data from the 52-week extension supported the ongoing safety of delgocitinib, with no new safety signals identified.¹⁵ Routine clinical vigilance remains warranted for signs of infection or unusual skin changes, but overall delgocitinib appears safe for sustained use and is well suited for a chronic-relapsing condition requiring long-term management. Delgocitinib does not carry a black box warning, distinguishing it from other topical JAK inhibitors such as ruxolitinib, which include this cautionary labeling.

Contraindications

Delgocitinib cream is contraindicated in individuals with known hypersensitivity to delgocitinib or the formulation’s components.¹⁷ It should not be applied to active, untreated infections such as impetigo, tinea manuum, or herpetic lesions, until appropriate antimicrobial therapy is initiated. While systemic absorption is low, caution is advised in patients with compromised immune function or those receiving systemic immunosuppressive medications.¹⁷ Use in combination with systemic JAK inhibitors is not recommended.

Regulatory Approval

Delgocitinib 2% cream is the first topical therapy specifically approved for CHD. It received regulatory approval from the European Medicines Agency in September 2024, followed by the U.S. Food and Drug Administration in July 2025 and Health Canada in August 2025.^17-19 Approval applies to adults with moderate-to-severe CHD who have an inadequate response to topical corticosteroids or cannot use them due to contraindications.^17-19 The recommended regimen is twice-daily application to all affected areas, with the option for continued or intermittent maintenance use based on clinical response.

Labeling includes precautions related to infection risk and vaccine administration similar to other immune-modulating therapies but does not require systemic laboratory monitoring. Importantly, delgocitinib cream does not carry a boxed warning, distinguishing it from systemic JAK inhibitors.

Discussion

Delgocitinib represents an important advance in the management of CHD. It addresses a longstanding need for a steroid-sparing topical therapy capable of controlling inflammation safely and effectively over long periods. Existing therapies such as topical corticosteroids and calcineurin inhibitors are often inadequate or poorly tolerated for chronic use, and systemic agents introduce risks that are excessive for many patients with localized disease.^9,20

Although ruxolitinib (a JAK1/JAK2 inhibitor) may be used for atopic-associated CHE, delgocitinib’s mechanism of action allows for broad suppression of inflammatory pathways while avoiding systemic toxicity. Its clinical benefits are notable across diverse CHE subtypes, including hyperkeratotic, vesicular, atopic-associated, and mixed-pattern disease. Early relief of pruritus and pain enhances patient comfort and supports adherence, while the absence of steroid-related adverse effects makes it suitable for prolonged therapy. The overall profile of delgocitinib, potent anti-inflammatory efficacy, durable maintenance, and strong safety, positions it as a foundational therapy for moderate-to-severe CHD.

An additional clinically relevant finding emerging from the DELTA 3 extension study concerns the durability of response following treatment withdrawal. A proportion of patients who achieved high levels of disease clearance maintained low disease activity after discontinuation, particularly those characterized as “super-responders.” This observation suggests that topical pan-JAK inhibition may not only suppress active inflammation but also interrupt self-perpetuating inflammatory circuits that sustain chronic disease. Although further investigation is needed to identify predictors of sustained remission, the potential for prolonged disease control after treatment cessation represents a meaningful therapeutic distinction in a chronic-relapsing condition where many agents require continuous application to maintain benefit.

Successful long-term management of CHD still requires identification and mitigation of triggers, consistent moisturization, and appropriate protective measures in the workplace and home. Delgocitinib should be integrated into a comprehensive care strategy, providing the anti-inflammatory backbone needed to break cycles of flare and relapse. With its approval, dermatologists now have a therapy designed specifically for CHD, providing a valuable tool for improving patient outcomes and quality of life.

Conclusion

CHD is a common, relapsing, and often debilitating condition that has historically been difficult to manage due to limitations of available therapies. Delgocitinib 2% cream offers a new, targeted approach by inhibiting multiple inflammatory pathways central to disease pathogenesis. Clinical trials demonstrate significant improvement in disease severity, symptoms, and quality of life, with sustained benefits during long-term use and a favorable safety profile. As the first approved non-steroidal topical therapy for moderate-to-severe CHD, delgocitinib represents a meaningful step forward in the treatment landscape. Its introduction supports the ongoing evolution of dermatologic therapeutics toward more precise, effective, and safer long-term treatment options for patients affected by chronic inflammatory skin diseases.